Opioids and Esophageal Function

• Status: Completed
• Trial end date: 2010-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate if opioid-induced effects on the pharynx and esophagus is centrally or peripherally mediated.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Region Örebro County
• Collaborator: Wyeth is now a wholly owned subsidiary of Pfizer
• Treatments: Analgesics, Opioid; Methylnaltrexone; Naltrexone

Criteria

Inclusion Criteria:

• 18 -40 year old healthy volunteers from both sexes.

• have signed and dated Informed Consent.

• willing and able to comply with the protocol for the duration of the trial.

Exclusion Criteria:

• anamnesis of pharyngoesophageal dysfunction.

• known or history of cardiac, pulmonary or neurological disease.

• ongoing medication.

• allergies to or history of reaction to methylnaltrexone, remifentanil or fentanyl analogues.

• pregnancy or breast feeding.

• participation in another clinical medicinal trial during the last 30 days or where follow-up is not completed.